James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

3 Big Stock Charts for Wednesday: CVS Health, Pfizer and Weyerhaeuser

The stock charts of CVS Health, Pfizer and Weyerhaeuser head into the midpoint of the week on the verge of major moves.

Tilray Prepares a Second Act That Could Rekindle TLRY Stock

Tilray stock has conspicuously taken a beating relative to the major cannabis players, but the underlying company's presence in the U.K. could change the narrative.

3 Big Stock Charts for Tuesday: Mosaic, Centene and American Airlines

The stock charts of Mosaic, Centene and American Airlines are moving into positions that portend more meaningful price changes.

Qualcomm’s New Processor Is An Underrated Game-Changer

QCOM stock has been all over the map of late, for understandable reasons. The new system on a chip, however, sets the stage for sustained growth from Qualcomm.

3 Big Stock Charts for Monday: KeyCorp, Procter & Gamble and Mohawk Industries

The stock charts of KeyCorp, Procter & Gamble and Mohawk Industries are ready to start the new trading week out with a bang.